Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxanes plus apatinib for advanced breast cancer
ChiCTR-OIC-16008894Phase 4Recruiting
- Sponsor
- The First Hospital of Lanzhou University
- Start
- Oct 2016
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in breast cancer, sponsored by The First Hospital of Lanzhou University. Primary endpoint: Progression-free survival (PFS). Started Oct 2016; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-OIC-16008894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16008894.